This redistribution of body fat is accompanied by metabolic perturbations including insulin resistance and hyperlipidemia, both hypertriglyceridemia and hypercholesterolemia (1, 4) , similar to metabolic syndrome X (5) . The prevalence of HIV-lipodystrophy (HIV-LD) is reported to be as high as 50% (1, 6) . The impact of changes in body habitus for individuals, and the widespread occurrence qualify this syndrome as a major cause for concern. Although many studies have associated this syndrome with the use of HIV protease inhibitors (1, (7) (8) (9) , other evidence suggests that fat redistribution is occurring in patients who have not taken protease inhibitors (2) and, indeed, that it was occurring before the introduction of protease inhibitors (10, 11) . Defining the etiology of the HIV-associated LD syndrome and its related metabolic abnormalities is an urgent priority.
In obesity and type 2 diabetes mellitus, two factors have been implicated in the etiology of insulin resistance. These factors are elevated free fatty acids (FFAs) and the cytokine tumor necrosis factor-␣ (TNF-␣). In both obesity and type 2 diabetes, insulin resistance is associated with elevated levels of FFAs (5, 12) . Elevated FFA levels alone are sufficient to induce insulin resistance without any underlying pathology (13, 14) , apparently by altering insulin signaling in skeletal muscle (15) . Additional markers of insulin resistance include increased abdominal fat in obesity (16) and type 2 diabetes mellitus (17) (18) (19) and elevated serum levels of insulin-like growth factor binding protein-1 (IGFBP-1) (20) .
Insulin resistance in obesity has been associated with a cytokine, TNF-␣, which is specifically implicated in the induction of insulin resistance (21) through inhibition of the insulin signaling cascade that regulates glucose uptake (22) . The role of TNF-␣ in the development of insulin resistance currently seen in HIV disease is not known. Cytokines, such as TNF-␣, were suspected in the wasting aspects of HIV infection, but low circulating levels failed to support this (23) (see also commentary by Grunfeld [24] ), whereas cytokines did contribute to hepatic lipogenesis (25) . With effective antiretroviral treatment, HIV-infected patients have improved disease control, as assessed by mortality (26) , low to undetectable viral load, and increased numbers of CD4 + lymphocytes (27) . The components of the TNF system are reduced in patients receiving highly active antiretroviral therapy (HAART) (28) but it would be instructive to know whether they remain depressed in HIV LD.
The present study was designed to characterize insulin resistance manifest in HIV patients who have the LD syndrome, but not overt diabetes, i.e., fasting, hyperglycemia. The degree of peripheral insulin resistance in these patients was assessed by the hyperinsulinemiceuglycemic clamp (29) . This method suppresses hepatic glucose output and provides an accurate measurement of the rate of insulin-stimulated glucose disposal in skeletal muscle. Insulin resistance was related to physiologic parameters known to be altered in insulin resistant states, that is, body fat distribution (30, 31) , circulating levels of FFAs (32) (33) (34) , and IGFBP-1 (20) . In addition, serum levels of soluble type 2 TNF-␣ receptor (sTNFR2) were assessed, inasmuch as elevated levels of sTNFR2 have not only been associated with the clinical course of HIV infection (35) , but in particular were found to correlate with insulin resistance in obesity (36) .
STUDY SUBJECTS AND METHODS
Those enrolled in the present study consisted of 12 healthy control study subjects, 14 study subjects infected with HIV without LD (denoted here as HIV), and 15 HIV-positive study subjects with the LD syndrome (HIV-LD). There were two exclusion criteria, diabetes, based on a random plasma glucose level >200 mg/dl or a fasting plasma glucose >126 mg/dl (based on diagnostic criteria in the Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus, 1997), and acute illness within the 3 months preceding the study. HIV-LD study subjects had self-reported loss of fat from the limbs and face with accumulation of fat in the abdomen and trunk, which was confirmed by physician assessment at the time of study. Control study subjects were matched for age and gender with the HIV and the HIV-LD groups. The HIV group consisted of 7 patients who were asymptomatic, 3 patients with AIDS, and 4 patients with AIDS and a prior history of weight loss. The HIV-LD group consisted of 7 asymptomatic patients and 8 patients with AIDS.
Most HIV-infected study subjects were receiving multidrug regimens and continued these medications during the study. In the HIV group, all patients except 2 were taking nucleoside reverse transcriptase inhibitors, 2 were taking nonnucleoside reverse transcriptase inhibitors, and 11 were taking protease inhibitors. Similarly in the HIV-LD group, all except 1 patient were taking reverse transcriptase inhibitors, 3 were taking nonnucleoside reverse transcriptase inhibitors, and 13 were taking protease inhibitors. No difference was found in the degree of peripheral fat loss or insulin resistance in those patients taking protease inhibitors and those who were not, although the number of patients who were not taking protease inhibitors was small.
Insulin Resistance
Insulin resistance was determined as the rate of glucose infused to maintain euglycemia during an insulin infusion (hyperinsulinemiceuglycemic clamp) (29) . Patients were admitted to our facility the night before the study. At 7 A.M., following baseline sampling, study subjects were infused with 1.2 mU insulin (Humulin, Eli Lilly, Indianapolis, IN, U.S.A.)/kg body weight/minute, designed to elevate plasma insulin levels to ∼40 U/ml. Although hepatic glucose production was not measured in this study, this rate of insulin infusion has been demonstrated to suppress hepatic glucose production in other insulin-resistant states (37) (38) (39) (40) . For example, Wise et al. (37) have demonstrated that hepatic glucose production in study subjects with type 2 diabetes is suppressed by insulin levels of ∼40 U/ml, when glucose concentra-tions are normalized (37) , suggesting that hepatic insulin resistance in type 2 diabetes is mediated by elevated glucose concentrations. Intravenous dextrose was administered to maintain plasma glucose, in all study subjects, at a level of 90 mg/dl assessed from arterialized samples, obtained by the heated hand technique (41) . Insulin resistance was determined from the amount of infused glucose needed to maintain euglycemia between hours 2 and 3. Insulin sensitivity is expressed as milligrams of glucose per kilogram of lean body mass (LBM) per minute. LBM was used to normalize for differences in body composition.
Circulating Parameters
Serum concentrations of the sTNFR2 were assessed by enzymelinked immunosorbent assay (ELISA, TNF RII CytoSet ELISA kit, Biosource International, Camarillo, CA, U.S.A.). HIV-1 RNA quantitation was by the Amplicor HIV-1 Monitor Test (Roche Diagnostic Systems, Branchburg, NJ, U.S.A.). Insulin was analyzed by radioimmunoassay (RIA, Diagnostic Products Corporation, Los Angeles, CA, U.S.A.). Serum IGFBP-1 was quantitated by ELISA (Diagnostic Systems Laboratories, Webster, TX, U.S.A.). FFAs were analyzed by the acyl-CoA oxidase method (Wako BioProducts, Richmond, VA, U.S.A.). Plasma glucose was determined by the glucose oxidase method, using a Beckman Glucose Analyzer II (Brea, CA, U.S.A.).
Body Composition
Body composition, including LBM, body fat mass (BFM), and the proportion of body fat in trunk and limbs was determined by dualenergy X-ray absorptiometry (DEXA) performed with a total body scanner (model DPS Lunar Radiation Co., Madison, WI, U.S.A.) (10) . Body weight, LBM, and BFM have been expressed per h 2 , as suggested by Quetelet for body mass index (BMI) (42) .
Statistical Analysis
All data are presented as mean ± standard error of the mean (SEM).
Comparison of the three study groups was made with an analysis of variance (ANOVA) and Student-Newman-Keuls test for multiple comparisons. Comparison of the control study subjects, stratified by body mass index, was made with Student's t-test. Differences were considered statistically significant when p < .05.
RESULTS
Healthy control study subjects, HIV study subjects, and HIV-LD study subjects, were similar in age. The BMI of the HIV-LD group tended to be more than that of the control or HIV group, although not significantly (Table 1) . To determine whether BMIs, in the range of the HIV-LD group, could account for the insulin resistance observed in HIV-LD the control group was subdivided into a low BMI subgroup (20.3 ± 0.4 kg/m 2 ; n ‫ס‬ 6), comparable with that in the HIV study subjects without LD, and a high BMI group (28.0 ± 2.0 kg/m 2 ; n ‫ס‬ 6), comparable with that of the HIV-LD group. Insulin sensitivity was similar in both subgroups, 11.4 ± 1.8 mg All values listed except viral load data, are mean ± standard error of the mean; the groups marked a differ from the groups marked b (p < .05). c Nadir CD4 lymphocytes (cells/l), the lowest recorded value, were available for a subset of patients, the n value for each group is listed in parentheses.
d Viral load data are listed as median (range), the limit of detection of the assay was 400 HIV RNA copies/ml. e The body mass index, the lean body mass (LBM) index, and the fat mass index were calculated from the component (total, lean, or fat) mass, in kilograms, obtained by dual-energy x-ray absorbtiometry (DEXA) and divided by the square of the height in meters (42) .
f Percentage of limb adiposity is the percentage of limb fat relative to the sum of fat from the limbs and trunk, determined by DEXA (10) .
g Insulin sensitivity is the rate of glucose disposal, normalized to lean body mass, assessed using the hyperinsulinemic-euglycemic clamp (29) . To convert the units from mg/dl to units expressed by The Système International Scale (mmol/L) for glucose and triglyceride levels, one should multiply the mg/dl values of glucose by 0.056 and of triglycerides by 0.0113. ND, not determined.
glucose/kg LBM/min for the low BMI control subgroup and 11.7 ± 1.2 mg glucose/kg LBM/min for the high BMI control subgroup. Insulin sensitivity of the HIV study subjects without LD was not significantly lower than that of the controls (9.2 ± 1.1 and 11.5 ± 1.0 mg glucose/kg LBM/minute, respectively) whereas the insulin sensitivity of the HIV-LD group was significantly lower that both other groups (5.4 ± 0.7 mg glucose/kg LBM/min; p < .05; Table 1 ) was significantly elevated in the HIV and HIV-LD groups compared with in the control group (p < .05). The LBM index of the low and high BMI control groups were similar (data not shown), indicating that the increased LBM in the HIV and HIV-LD groups was not a consequence of increased BMI.
Assignment to the HIV-LD group was by self-report and physician-confirmed loss of facial and limb fat with increased trunk fat. Patients in this group had reduced proportion of limb fat and increased proportion of trunk fat, determined by DEXA. The proportion of body fat localized to the limbs in HIV-LD patients (34.8%) was significantly diminished (p < .05), compared with the HIV group (48.2%) and the control group (52.4%; Table 1).
The control group insulin sensitivity was 11.5 ± 1.0 mg glucose/kg LBM/min (Table 1, Fig. 1) . A similar value was observed in HIV patients (9.2 ± 1.1 mg glucose/kg LBM/minute). In HIV-LD patients, however, the amount of glucose infused to maintain euglycemia was 5.4 ± 0.7 mg glucose/kg LBM/minute, a reduction of 53% relative to the control group (p < .05). This reduction in the amount of glucose needed to maintain euglycemia during hyperinsulinemia indicates a twofold reduction in insulin sensitivity. This decrease in insulin sensitivity was correlated with the reduction in the percentage of limb fat (r ‫ס‬ 0.60; p ‫ס‬ .0001; Fig. 2 ).
In the non-LD HIV group, 6 of 14 patients had viral loads below the detection limit of the assay (400 HIV RNA copies/ml) and in the HIV-LD group, 8 of 15 were below the limit of detection. For the HIV-infected patients with measurable viral loads, insulin sensitivity did not correlate with viral load (r ‫ס‬ 0.229; p ‫ס‬ .45; data not shown). In addition, within the HIV-LD group, individuals with viral loads >400 HIV RNA copies/ml (n ‫ס‬ 7) and <400 HIV RNA copies/ml (n ‫ס‬ 8) had similar insulin sensitivities (5.89 ± 1.26 and 4.95 ± 1.05 mg glucose/kg LBM/minute, respectively).
At the time of screening, random plasma glucose levels were similar in all groups (data not shown). Following an overnight fast, basal glucose levels were higher in the HIV-LD group, but not significantly ( Table 1) . The fasting insulin and triglyceride levels were significantly higher in the HIV-LD group than in both the control and HIV groups (p < .05; Table 1 ). The HIV-LD cholesterol levels (225 ± 15) were significantly greater that those of the HIV group (182 ± 8; p < .05), but not those of the control group (194 ± 6).
Patients in both the HIV and HIV-LD groups were doing well clinically, with decreasing levels of HIV
FIG. 1.
Insulin sensitivity in control study subjects, study subjects with HIV, and study subjects with HIV lipodystrophy. The rate of glucose infusion (mg/kg lean body mass/minute) required to maintain plasma glucose at 90 mg/dl, in response to infused insulin (1.2 mU insulin/kg/minute) from 120 to 180 minutes after the start of the insulin infusion during the hyperinsulinemic-euglycemic clamp. Data are expressed as mean ± standard error of the mean, the group marked b differed significantly from the two groups marked a, p < .05.
RNA copies and increased numbers of CD4
+ lymphocytes, relative to recorded nadir levels ( Table 1) . However, all these patients had significantly elevated circulating levels of sTNFR2, relative to those in the control study subjects (p < .05; Fig. 3 ). More significantly, the HIV-LD group had greater levels of the sTNFR2 than the HIV group (p < .05; Fig. 3) . Surprisingly, there was no significant difference in the soluble type 2 TNF-␣ receptor levels in patients with viral loads >400 copies/ml and <400 copies/ml; both groups had soluble type 2 TNF-␣ receptor levels of 5.5 ± 0.6 ng/ml. Levels of the sTNFR2 in the two HIV-infected groups did not correlate with viral load in those study subjects with measurable viral loads (r ‫ס‬ 0.28; p ‫ס‬ .35). These elevated levels of the sTNFR2 were associated with diminished insulin sensitivity (r ‫ס‬ 0.59; p ‫ס‬ .0001; Fig. 4) .
The fasting levels of IGFBP-1 ( Fig. 5) and FFAs ( Fig. 5) were not increased in the HIV-LD group. The IGFBP-1 levels of the HIV-LD group were significantly lower (p < .05) than those of the control (55%) and the HIV (50%) groups (Fig. 5) , but similar to those of the high BMI control subgroup (data not shown). IGFBP-1 levels in all groups were responsive to insulin during the hyperinsulinemic-euglycemic clamp (Fig. 5) . FFAs levels, however, were less depressed by insulin in the HIV-LD group than in the control and HIV groups (Fig. 5) . The ability of insulin to suppress serum FFAs, expressed as the percentage reduction in serum FFA levels under
FIG. 2.
Correlation of insulin resistance with percentage of limb fat in control study subjects and study subjects with HIV and with HIV lipodystrophy. Rates of glucose infusion required to maintain euglycemia during the period of 120 to 180 minutes of insulin infusion (1.2 mU/kg/minute) plotted against the percentage of total body fat distributed in the limbs in control study subjects (᭺), study subjects with HIV (ᮀ), and study subjects with HIV lipodystrophy ⌬ (r = 0.60; p = .0001).
FIG. 3.
Serum concentration of the soluble type 2 tumor necrosis factor-␣ (TNF-␣) receptor in HIVuninfected study subjects, study subjects with HIV, and study subjects with HIV lipodystrophy. The serum concentration of the soluble type 2 TNF-␣ receptor is expressed in ng/ml. Significant differences were found among the groups marked a, b, and c (p < .05).
hyperinsulinemic conditions, relative to fasting conditions, was significantly diminished in the HIV-LD group (56.5 ± 7.9) compared with the control group (88.3 ± 4.6) or the HIV group (80.8 ± 3.1; p < .05). The diminished sensitivity of FFA levels to insulin was significantly correlated with the glucose disposal rates from the clamp studies (r ‫ס‬ 0.5552; p ‫ס‬ .0002; Fig. 6 ).
DISCUSSION
In the present study, patients with clinically defined HIV LD had a 34% reduction in percentage of limb fat, relative to findings in the control group (Table 1) . These patients exhibited severe insulin resistance (Fig. 1) of a magnitude similar to that seen with type 2 diabetes mellitus (43, 44) . The loss of limb fat was highly correlated (p ‫ס‬ .0001) with insulin resistance, as shown in Figure  2 , demonstrating, for the first time, that insulin resistance accompanies the pathologic loss of peripheral fat. The well recognized association between trunk adiposity and insulin resistance appears not to be a significant factor in HIV-LD. When patients with HIV-LD were stratified into groups with the greatest versus the least amount of trunk adipose tissue (19.0 kg versus 6.8 kg trunk fat), the two groups had similar insulin sensitivities (data not shown). An alarming feature of HIV-LD is that in the context of a routine clinic examination, the HIV-LD group may be unremarkable, with normal screening glucose levels (data not shown), and elevated triglyceride levels, a feature that has become an expected finding of HIV infection (45) . The HIV-LD patients also had significantly elevated levels of the sTNFR2 (Fig. 3) . This finding is of interest, given that these patients are doing well clinically, with well-controlled HIV replication and improved numbers of CD4 + lymphocytes. Furthermore, insulin resistance in the HIV-infected population was highly correlated (p ‫ס‬ .0001) with the serum levels of the sTNFR2 (Fig. 4) , suggesting that inflammation may contribute to the pathophysiology of LD and insulin resistance. At present, the cellular source of the sTNFR2 is 
FIG. 4.
Correlation of insulin sensitivity with the serum concentration of the soluble type 2 tumor necrosis factor-␣ (TNF-␣) receptor, in control study subjects, study subjects with HIV, and those with HIV lipodystrophy. The rates of glucose infusion required to maintain euglycemia during the period 120 to 180 minutes of insulin infusion (1.2 mU/kg/minute) plotted against serum concentrations of the soluble type 2 TNF-␣ receptor in control study subjects (᭺), study subjects with HIV (ᮀ), and study subjects with HIV lipodystrophy ⌬ (r = 0.59; p = .0001).
unknown, and investigations are currently under way to identify this source.
Type 2 diabetes mellitus is characterized by peripheral insulin resistance and fasting hyperglycemia. The latter is indicative of hepatic insulin resistance, resulting from the inability of endogenous insulin to suppress hepatic glucose production. None of these study subjects were hyperglycemic at screening. This afforded the opportunity to examine insulin resistance associated with HIV-LD, in the absence of overt diabetes. Following an overnight fast, glucose levels of the HIV-LD study subjects were elevated, but within the normal range (Table 1) , and insulin levels were significantly elevated (threefold relative to those of controls). Thus, although the HIV-LD study subjects appear normal at screening, they exhibit marked peripheral insulin resistance during the stress of the hyperinsulinemic-euglycemic clamp (Fig. 1) . The HIV-LD study subjects have fasting levels of IGFBP-1 below normal, unlike in type 2 diabetes mellitus wherein IGFBP-1 levels are elevated (20) . This unique ability of the liver to suppress fasting glucose and IGFBP-1 production may be linked mechanistically. The genetic regulatory elements by which insulin controls the gene expression of the rate-limiting enzyme of gluconeogenesis, phosphoenolpyruvate carboxykinase, are identical to those controlling IGFBP-1 expression (46), indicating that this aspect of hepatic insulin action has not become insulin resistant, in contrast to skeletal muscle and adipose tissue. One of the exclusion criteria for participating in this study was a fasting plasma glucose level >126 mg/dl, to exclude individuals with frank diabetes. A recent report (8) documented a group of HIV-infected individuals with frank diabetes, based on hyperglycemia and hyperinsulinemia under fasting conditions. In contrast, the present study and that of Walli et al. (47) clearly demonstrate that there are also HIV-infected individuals who are severely insulin resistant, but whose fasting glucose levels remain within the normal range. At present, it is unknown whether these individuals will progress to frank diabetes, but the association of insulin resistance with hypertriglyceridemia places them at risk for the development of vascular disease.
The HIV-LD subjects in our study have normal fasting serum FFA levels in the presence of slightly elevated levels of insulin. However, insulin resistance in adipose tissue is revealed by the clamp studies. The reduced capacity for suppression of FFA levels by insulin in HIV-LD study subjects is demonstrated by the correlation of insulin sensitivity with hyperinsulinemic suppression of serum FFA levels shown in Figure 6 . The subtle resistance of adipose tissue to insulin in HIV-LD may result from increased truncal fat, given that abdominal fat is more resistant than peripheral fat to the antilipolytic effects of insulin (48) .
The clinical characteristics of HIV-LD bear a resemblance to the rare forms of acquired and congenital lipodystrophies (49) (50) (51) (52) , as well as an animal model of lipoatrophic diabetes (53) . The congenital and acquired generalized lipodystrophies are characterized by loss of both trunk and limb fat, increased LBM (51), severe insulin resistance (52), normal levels of FFAs (51, 52) , and suppressed levels of IGFBP-1 (50). All these characteristics, except loss of trunk fat, are also shared with HIV-LD, suggesting that loss of peripheral fat alone may be sufficient to induce a state of peripheral insulin resistance. The increases in the LBM index of the HIV-LD group may also be causally linked to the LD syndrome.
Fat distribution, physiologic parameters, and serum markers associated with different insulin-resistant states are summarized in Table 2 . These data demonstrate that the insulin resistance in HIV-LD is distinct from that associated with most forms of type 2 diabetes, based on FIG. 6. Correlation of insulin sensitivity with suppression of free fatty acid levels during hyperinsulinemic clamp. The rates of glucose infusion required to maintain euglycemia during the period 120 to 180 minutes of insulin infusion (1.2 mU/kg/minute) plotted against suppression of free fatty acid levels, expressed as the ratio of free fatty acid levels under hyperinsulinemic conditions to those under basal conditions in controls study subjects (᭺), study subjects with HIV (ᮀ), and study subjects with HIV lipodystrophy ⌬ (r = 0.5552; p = .0002).
hepatic insulin sensitivity, reflected by both fasting glycemia (Table 1) and IGFBP-1 levels (Fig. 5) , and insulin sensitivity of adipose tissue reflected by fasting FFA levels (Fig. 5) . The distinction between HIV-LD and obesity, although not so dramatic as with type 2 diabetes, is still clearly demonstrated by the differences in fasting FFA levels ( Table 2) . Table 2 also demonstrates that the insulin resistant state associated with HIV-LD has most in common with the exceedingly rare congenital and acquired lipodystrophies (52) . The similarities include the loss of peripheral fat, increased LBM, severe insulin resistance, normal fasting FFA levels, and reduced IGFBP-1 levels. Although both increased trunk fat and elevated FFAs are commonly associated with insulin resistance, the presence of insulin resistance in acquired and congenital LD with loss of trunk fat and normal FFAs, suggests that loss of peripheral fat alone may also be sufficient to cause insulin resistance.
The elevation of sTNFR2 levels in the HIV-LD group is surprising and suggests that the stimulus for the shedding of the type 2 TNF-␣ receptor is associated with the development of insulin resistance in this group (Fig. 4) . Elevated sTNFR2 levels are also seen in association with insulin resistance in myotonic dystrophy (54) and obesity (36) . The patients with HIV-LD have elevated TNF receptor levels despite the fact that they are doing well clinically and have been free of acute illness for >3 months. The lack of correlation between viral load and sTNFR2 levels may indicate that the shedding of the TNF receptors may be unrelated to the activity of the HIV infection. The correlation of insulin resistance with elevated sTNFR2 suggests that an inflammatory stimulus may contribute to the induction of HIV-LD and insulin resistance.
The syndrome (or syndromes) of HIV-associated acquired LD is an alarming development in the treatment of HIV infection. The potential for the accelerated development of type 2 diabetes mellitus and coronary artery disease, in this at risk population, places a high priority on establishing the etiology and developing rational therapies for this metabolic condition. The data of the present study provide strong evidence that individuals infected with HIV who have experienced body fat redistribution from the limbs and face to the trunk have a syndrome that is closely related to the acquired and congenital, generalized LD. The association of this syndrome with elevated levels of the soluble type 2 TNF-␣ receptor indicates an that an inflammatory process is associated with the loss of peripheral insulin sensitivity. In conclusion, this study emphasizes that HIV patients with fat redistribution and elevated triglyceride levels are likely to be severely insulin resistant in the periphery, even with normal screening plasma glucose levels, and should be observed closely to prevent their progression to premature type 2 diabetes mellitus and coronary artery disease. 
